Heme deficiency in Alzheimer's disease: A possible connection to porphyria

Journal of Biomedicine and Biotechnology

Volumn 2006, Issue , 2006, Pages

  Dwyer, Barney E ^a,b   Stone, Meghan ^a   Zhu, Xiongwei ^c   Perry, George ^c   Smith, Mark A ^c  

^a Department of Veterans Affairs Regional Office White River Junction   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEME;

ACUTE DISEASE; ALZHEIMER DISEASE; BIOSYNTHESIS; CLINICAL FEATURE; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; GENETIC TRAIT; HEME DEFICIENCY; HEPATIC PORPHYRIA; HUMAN; PATHOGENESIS; PORPHYRIA; PROTEIN DEFICIENCY; REVIEW;

EID: 33746824988     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/JBB/2006/24038     Document Type: Review

References (48)

1. M A Smith Alzheimer disease. International Review of Neurobiology 1998 42 1 54 9476170
2. S W Scheff sscheff@email.uky.edu D A Price Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies. Neurobiology of Aging 24 8 2003 1029 1046
3. L S Schneider lschneid@usc.edu K S Dagerman Psychosis of Alzheimer's disease: clinical characteristics and history. Journal of Psychiatric Research 38 1 2004 105 111
4. B E Dwyer A K Raina G Perry M A Smith Homocysteine and Alzheimer's disease: a modifiable risk? Free Radical Biology and Medicine 36 11 2004 1471 1475
5. B E Dwyer A Takeda X Zhu G Perry M A Smith Ferric cycle activity and Alzheimer disease. Current Neurovascular Research 2 3 2005 261 267
6. H Atamna hatamna@chori.org W H II Frey A role for heme in Alzheimer's disease: heme binds amyloid β and has altered metabolism. Proceedings of the National Academy of Sciences of the United States of America 101 30 2004 11153 11158
7. G H Elder R J Hift P N Meissner The acute porphyrias. The Lancet 349 9065 1997 1613 1617
8. U A Meyer M M Schuurmans R LP Lindberg Acute porphyrias: pathogenesis of neurological manifestations. Seminars in Liver Disease 18 1 1998 43 52
9. H L Bonkovsky G F Barnard The porphyrias. Current Treatment Options in Gastroenterology 2000 3 6 487 500 11096610
10. P N Meissner R J Hift R E Kirsch I M Arias J L Boyer F V Chisari N Fausto D Schacter D A Shafritz The porphyrias. The Liver: Biology and Pathobiology 4th Lippincott Williams and Wilkins Philadelphia, Pa 2001 311 329
11. J W Albers jwalbers@umich.edu J K Fink Porphyric neuropathy. Muscle and Nerve 30 4 2004 410 422
12. K E Anderson J R Bloomer H L Bonkovsky Recommendations for the diagnosis and treatment of the acute porphyrias. Annals of Internal Medicine 142 6 2005 439 450
13. M N Badminton badmintonmn@Cardiff.ac.uk G H Elder Molecular mechanisms of dominant expression in porphyria. Journal of Inherited Metabolic Disease 28 3 2005 277 286
14. C Handschin J Lin J Rhee Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1α Cell 122 4 2005 505 515
15. D Li PGC-1α: looking behind the sweet treat for porphyria. Cell 122 4 2005 487 489
16. R LP Lindberg R Martini M Baumgartner Motor neuropathy in porphobilinogen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria. Journal of Clinical Investigation 103 8 1999 1127 1134
17. R LP Lindberg C Porcher B Grandchamp Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria. Nature Genetics 12 2 1996 195 199
18. A Johansson Annika.Johansson@labmed.ki.se C Möller J Fogh P Harper Biochemical characterization of porphobilinogen deaminase-deficient mice during phenobarbital induction of heme synthesis and the effect of enzyme replacement. Molecular Medicine 9 9-12 2003 193 199
19. P A Wyss S Boynton J Chu K S Roth Tissue distribution of succinylacetone in the rat in vivo: a possible basis for neurotoxicity in hereditary infantile tyrosinemia. Biochimica et Biophysica Acta 1182 3 1993 323 328
20. Z F Soonawalla T Orug M N Badminton Liver transplantation as a cure for acute intermittent porphyria. The Lancet 363 9410 2004 705 706
21. C Solis A Martinez-Bermejo T P Naidich Acute intermittent porphyria: studies of the severe homozygous dominant disease provides insights into the neurologic attacks in acute porphyrias. Archives of Neurology 61 11 2004 1764 1770
22. P Mustajoki K Timonen A Gorchein A M Seppalainen E Matikainen R Tenhunen Sustained high plasma 5-aminolaevulinic acid concentration in a volunteer: no porphyric symptoms. European Journal of Clinical Investigation 1992 22 6 407 411 1633836
23. X Zhu A K Raina G Perry M A Smith Alzheimer's disease: the two-hit hypothesis. Lancet Neurology 3 4 2004 219 226
24. L Zecca luigi.zecca@itb.cnr.it M BH Youdim P Riederer J R Connor R R Crichton Iron, brain ageing and neurodegenerative disorders. Nature Reviews. Neuroscience 5 11 2004 863 873
25. J R Jr Paterniti C IP Lin D S Beattie δ-Aminolevulinic acid synthetase: regulation of activity in various tissues of the aging rat. Archives of Biochemistry and Biophysics 191 2 1978 792 797
26. R J Castellani P LR Harris L M Sayre Active glycation in neurofibrillary pathology of Alzheimer disease: N ε-(carboxymethyl) lysine and hexitol-lysine. Free Radical Biology and Medicine 31 2 2001 175 180
27. F Caballero E Gerez A Batlle batlle@mail.retina.ar E Vazquez Preventive aspirin treatment of streptozotocin induced diabetes: blockage of oxidative status and revertion of heme enzymes inhibition. Chemico-Biological Interactions 126 3 2000 215 225
28. R Castellani K Hirai G Aliev Role of mitochondrial dysfunction in Alzheimer's disease. Journal of Neuroscience Research 70 3 2002 357 360
29. H Atamna D W Killilea A N Killilea B N Ames Heme deficiency may be a factor in the mitochondrial and neuronal decay of aging. Proceedings of the National Academy of Sciences of the United States of America 99 23 2002 14807 14812
30. H Atamna J Liu B N Ames bnames@uclink4.berkeley.edu Heme deficiency selectively interrupts assembly of mitochondrial complex IV in human fibroblasts: relevance to aging. Journal of Biological Chemistry 276 51 2001 48410 48416
31. B L Cussimanio A A Booth P Todd B G Hudson R G Khalifah rkhalifah@biostratum.com Unusual susceptibility of heme proteins to damage by glucose during non-enzymatic glycation. Biophysical Chemistry 105 2-3 2003 743 755
32. M A Smith R K Kutty P L Richey Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. American Journal of Pathology 145 1 1994 42 47
33. H M Schipper S Cisse E G Stopa Expression of heme oxygenase-1 in the senescent and Alzheimer-diseased brain. Annals of Neurology 37 6 1995 758 768
34. D Howlett P Cutler S Heales P Camilleri Patrick_Camilleri@sbphrd.com Hemin and related porphyrins inhibit β-amyloid aggregation. FEBS Letters 417 2 1997 249 251
35. B W Ahn D U Song Y D Jung Detection of β-amyloid peptide aggregation using DNA electrophoresis. Analytical Biochemistry 284 2 2000 401 405
36. T Chernova tc28@le.ac.uk P Nicotera A G Smith Heme deficiency is associated with senescence and causes suppression of N-methyl-D-aspartate receptor subunits expression in primary cortical neurons. Molecular Pharmacology 69 3 2006 697 705
37. A Sengupta T Hon L Zhang lz2115@columbia.edu Heme deficiency suppresses the expression of key neuronal genes and causes neuronal cell death. Molecular Brain Research 137 1-2 2005 23 30
38. G Perry A Nunomura A D Cash Reactive oxygen: its sources and significance in Alzheimer disease. Journal of Neural Transmission, Supplement 62 2002 69 75
39. H P Monteiro D SP Abdalla A Faljoni-Alario E JH Bechara Generation of active oxygen species during coupled auto oxidation of oxyhemoglobin and δ-aminolevulinic acid. Biochimica et Biophysica Acta 1986 881 1 100 106 3081047
40. T Douki J Onuki M HG Medeiros E JH Bechara J Cadet P Di Mascio pdmascio@quim.iq.usp.br DNA alkylation by 4,5-dioxovaleric acid, the final oxidation product of 5-aminolevulinic acid. Chemical Research in Toxicology 11 2 1998 150 157
41. P Di Mascio pdmascio@iq.usp.br P C Teixeira J Onuki DNA damage by 5-aminolevulinic and 4,5-dioxovaleric acids in the presence of ferritin. Archives of Biochemistry and Biophysics 373 2 2000 368 374
42. J Onuki Y Chen P C Teixeira Mitochondrial and nuclear DNA damage induced by 5-aminolevulinic acid. Archives of Biochemistry and Biophysics 432 2 2004 178 187
43. P I Oteiza C G Kleinman M Demasi E JH Bechara 5-Aminolevulinic acid induces iron release from ferritin. Archives of Biochemistry and Biophysics 316 1 1995 607 611
44. M EM Rocha A MDC Ferreira E JH Bechara Roles of phosphate and an enoyl radical in ferritin iron mobilization by 5-aminolevulinic acid. Free Radical Biology and Medicine 29 12 2000 1272 1279
45. M EM Rocha F Dutra B Bandy Oxidative damage to ferritin by 5-aminolevulinic acid. Archives of Biochemistry and Biophysics 409 2 2003 349 356
46. P Mustajoki R Kauppinen L Lannfelt L Lilius J Koistinen Frequency of low erythrocyte porphobilinogen deaminase activity in Finland. Journal of Internal Medicine 231 4 1992 389 395
47. Y Nordmann H Puy V Da Silva Acute intermittent porphyria: prevalence of mutations in the porphobilinogen deaminase gene in blood donors in France. Journal of Internal Medicine 242 3 1997 213 217
48. M I Kamboh ikamboh@hgen.pitt.edu Molecular genetics of late-onset Alzheimer's disease. Annals of Human Genetics 68 4 2004 381 404